BioSpace News Archive

INmune Bio, Inc. (NASDAQ: INMB) (the “Company”), a clinical-stage immunology company focused on developing treatments that harness the patient’s innate immune system to fight disease was featured on a Fox Business News segment. Fox Business News reports: “INmune Bio CEO, President and acting CMO Dr. Raymond Tesi, M.D. talks about INmune Bio’s proposed phase two human trials of possible treatment of coronavirus patients using an ant

Flu and pneumonia vaccinations are associated with reduced risk of Alzheimer’s disease, according to new research reported at the Alzheimer’s Association International Conference® 2020.

The advanced therapy medicinal products market may observe growth across the forecast period of 2019-2029 on the back of the advancements in the biotechnology sector on a large scale.

Daiichi Sankyo Company, Limited announced that it has entered into a global development and commercialization agreement with AstraZeneca for Daiichi Sankyo’s DS-1062, a TROP2 directed DXd antibody drug conjugate, currently in phase 1 clinical development for non-small cell lung cancer and triple negative breast cancer.

Savvy players in the global tuberculosis testing market are banking upon strategic acquisitions to grow their shares.

Immunoglobulins are highly purified, sterile specific medical therapy solutions containing gammaglobulin G in a concentration of 95% or more.

This report analyzes the current scenario and future prospects of the global diabetic foot ulcers treatment market. Rise in geriatric population and increase in people suffering from chronic diseases such as diabetes and HIV are expected to increase at a rapid pace in the next few years.

BetterLife Pharma Inc. is pleased to provide an update on the proposed acquisition of Altum Pharmaceuticals Inc. (“Altum”) and its upcoming clinical programs.

Agendia, Inc., a world leader in precision oncology for breast cancer, announced the publication of MINDACT trial data in the July 27 issue of Communications Biology, a Nature Publishers Journal.

400 Patients Expected to be Enrolled in CPRIT-Backed Artificial Intelligence Development Study in Breast Cancer